Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biktarvy

Gilead Sciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Biopharma looks to genome editing platform to discover hepatitis B cure

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

Gilead Sciences

Gilead’s Biktarvy gets European approval, setting up battle with GSK

The drug could offset Gilead's disappointing hep C franchise

- PMLiVE

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

A rapid round up of pharma, biotech and healthcare news

Gilead Sciences

Gilead and Verily team up to map inflammatory diseases

Computational analysis could provide deeper understanding of disease

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

- PMLiVE

Morning brief: Allergan’s migraine results, Biktarvy approved in Europe and more

A rapid run-down of news in pharma, biotech and healthcare

Gilead Sciences

Gilead says switching studies back new HIV therapy Biktarvy

Patients who switched from rival Triumeq could maintain viral suppression over the trial period

Gilead Sciences

Gilead study resurrects HIV eradication hope

Intends to start human trials of its improved bNAb candidate

Gilead Sciences

Gilead signs $3bn-plus gene-editing deal with Sangamo

Will use the platform for new cell-based cancer therapies

- PMLiVE

Gilead’s triple HIV drug approval prompts GSK lawsuit

ViiV claims bictegravir infringes its patent estate

- PMLiVE

Gilead adds to CAR-T assets with Cell Design Labs buyout

Gains full control of the biotherapeutics firm following its acquisition of Kite Pharma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links